QuantaMatrix wins €11 million bid to supply microbiology diagnostics to French public hospitals < Pharma < Article

QuantaMatrix, an in vitro diagnostics company, said on Thursday that it won a tender valued at €11 million ($15.4 billion) to exclusively supply its direct & Rapid Antimicrobial Susceptibility Test (dRAST) for four years to public hospitals in France.

QuantaMatrix was selected by Union des Hôpitaux pour les Achats (UniHA), France's public hospital purchasing organization, over other global bidders based on its unique combination of two panels covering both Gram-negative and Gram-positive bacteria, the company said. Its differentiated product technology offers fully automated instrumentation, demonstrated clinical utility through published papers in Europe, and its ability to demonstrate the revenue benefits of rapid antimicrobial susceptibility testing to hospitals.

While conventional antimicrobial susceptibility testing takes 60 hours, dRAST reduces testing time by up to 50 hours by minimizing manual labor, and results are available quickly. By prescribing the right antimicrobials to patients at the right time, dRAST reduces average healthcare costs and resource days, and improves bed turnover, allowing more patients to benefit from healthcare, explained a QuanatMatrix company official.

QuantaMatrix has installed its dRAST solution at Henri Mondor Hospital and the European Hospital Georges Pompidou over the past two years, where it was evaluated to ensure compliance with hospital and laboratory regulations, analytical performance, and no discrepancies in results between laboratories.

UniHA is the largest purchasing union in France, accounting for more than 90 percent of the public hospital procurement market for which the procurement budget has steadily increased from €800 million in 2008 to €5.9 billion in 2022. According to market research firm, Insights Global, the global sepsis diagnostics market is estimated to reach $1.65 billion by 2028 growing at a CAGR of 10.5 percent during the period 2022-2028.

“Although it is difficult to win these tenders, the advantage is that QuantMatrix can now capture a large share of the market at once, rather than selling through individual hospitals," said QuantaMatrix CEO Kwon Sung-hoon. “Winning the UniHA tender is an opportunity to accelerate the adoption of dRAST to help clinicians provide better care, reduce antimicrobial resistance, and continue to bring our dRAST solution to more sepsis patients.”

QuantaMatrix’s dRAST has already been supplied to Germany, the U.K., Spain, Switzerland, Norway, and Israel and is now preparing for full-scale entry into the French market.

tweet window.twttr=(function(d,s,id){var t,js,fjs=d.getElementsByTagName(s)[0];if(d.getElementById(id)){return}js=d.createElement(s);js.id=id;js.src="https://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);return window.twttr||(t={_e:[],ready:function(f){t._e.push(f)}})}(document,"script","twitter-wjs"));